281 related articles for article (PubMed ID: 7009993)
1. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer.
McKneally MF; Maver C; Lininger L; Kausel HW; McIlduff JB; Older TM; Foster ED; Alley RD
J Thorac Cardiovasc Surg; 1981 Apr; 81(4):485-92. PubMed ID: 7009993
[TBL] [Abstract][Full Text] [Related]
2. Regional immunotherapy with intrapleural BCG for lung cancer.
McKneally MF; Maver C; Kausel HW; Alley RD
J Thorac Cardiovasc Surg; 1976 Sep; 72(3):333-8. PubMed ID: 785107
[TBL] [Abstract][Full Text] [Related]
3. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group.
J Thorac Cardiovasc Surg; 1981 Nov; 82(5):649-57. PubMed ID: 7029149
[TBL] [Abstract][Full Text] [Related]
4. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin.
Yasumoto K; Manabe H; Yanagawa E; Nagano N; Ueda H; Hirota N; Ohta M; Nomoto K; Azuma I; Yamamura Y
Cancer Res; 1979 Aug; 39(8):3262-7. PubMed ID: 222448
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results of combined surgery and adjuvant Bacillus Calmette-Guérin plus levamisole treatment of resectable lung cancer.
Wright PW; Hill LD; Peterson AV; Pinkham R; Johnson L; Ivey T; Bernstein I; Bagley C; Anderson R
Cancer Treat Rep; 1978 Nov; 62(11):1671-5. PubMed ID: 215304
[TBL] [Abstract][Full Text] [Related]
8. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
9. BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis.
Hadźiev S; Mandulova P; Kavaklieva-Dimitrova J; Penev K; Spassova M; Madźarova S
Neoplasma; 1982; 29(1):93-110. PubMed ID: 6280082
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial.
Matthay RA; Mahler DA; Beck GJ; Loke J; Baue AE; Carter DC; Mitchell MS
Cancer Res; 1986 Nov; 46(11):5963-8. PubMed ID: 3530442
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
Winters WD; Lamm DL
Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoimmunotherapy for gastric carcinoma.
Makowka L; Falk RE; Ambus U; Bugala R; Landi S
Can J Surg; 1980 Sep; 23(5):429-31. PubMed ID: 6159957
[TBL] [Abstract][Full Text] [Related]
14. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of intraoperative pleural lavage cytology for lung cancer without carcinomatous pleuritis: importance in patients with early stage disease during long-term follow-up.
Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Takenaka A; Nakayama T; Yoneda G
Eur J Cardiothorac Surg; 2009 Feb; 35(2):337-42. PubMed ID: 19041255
[TBL] [Abstract][Full Text] [Related]
16. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.
Leblanc B; Duclos AJ; Bénard F; Valiquette L; Paquin JM; Lapointe S; Mauffette F; Pharand D; Faucher R; Drouin G; Perreault JP
Can J Urol; 2000 Feb; 7(1):944-8. PubMed ID: 11121250
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
18. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
Ariyan S; Kirkwood JM; Mitchell MS; Nordlund JJ; Lerner AB; Papac RJ
Surgery; 1982 Sep; 92(3):459-63. PubMed ID: 7112396
[TBL] [Abstract][Full Text] [Related]
19. Survival of lung cancer patients treated with BCG and/or a soluble BCG fraction (F70) after surgery, radiotherapy and chemotherapy.
Hadźiev S; Kavaklieva-Dimitrova J; Mandulova P; Madźarova S; Spassova M
Neoplasma; 1980; 27(1):83-94. PubMed ID: 7374861
[TBL] [Abstract][Full Text] [Related]
20. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
